Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 19, 2021Open Access

Decreased neutralization of SARS-CoV-2 global variants by therapeutic anti-spike protein monoclonal antibodies

View Full Paper
Ask AI
Bookmark
Share

Authors

TTTakuya TadaNew York UniversityBDBelinda M. DcostaNew York UniversityHZHao ZhouYunnan University

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Tada et al. (2021) studied this question.

synapsesocial.com/papers/6aaf6e54debf0b2b005d2e03https://doi.org/10.1101/2021.02.18.431897
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma2021 · 309 citations
  2. 2Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants2020 · 1,470 citations
  3. 3Transmission of SARS-CoV-2 Lineage B.1.1.7 in England: Insights from linking epidemiological and genetic data2021 · 653 citations
  4. 4Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host2020 · 1,390 citations
  5. 5An ACE2 Microbody Containing a Single Immunoglobulin Fc Domain Is a Potent Inhibitor of SARS-CoV-22020 · 87 citations